This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $667,118.00 to The Regents of the University of California, San Francisco to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The 5-year project, beginning on April 1, 2025, will systematically analyze pancreatic cancer cell lysosomes to identify key proteins that enable pro-survival catabolic...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $523,480.00 to the Dana-Farber Cancer Institute, Inc. to conduct research aimed at overcoming resistance to KRAS inhibitor therapies in pancreatic ductal adenocarcinoma (PDAC). The research will focus on defining how dysregulated iron metabolism and autophagy-dependent mechanisms contribute to both acute adaptive and long-term acquired resistance to KRAS inhibition in PDAC. The goal is to...
The National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) federal grant program, awarded a $342,397 Project Grant to Wayne State University to investigate the relationship between MAIT cells and the microbiome in pancreatic cancer liver metastasis. The award period runs from September 30, 2024 to April 28, 2028. The Cancer Research Manpower program supports diverse cancer-related research, training, and career development initiatives across academic and medical...
This $128,199 Project Grant, awarded on August 14, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower), supports research to determine the role of the lipid kinase PIKFYVE in regulating metabolic homeostasis in pancreatic ductal adenocarcinoma (PDAC) and explore the synergistic effects of inhibiting PIKFYVE and the KRAS-MAPK signaling pathway. The research aims to delineate the functional relationship between PIKFYVE and lipid homeostasis in PDAC, establish a rationale...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $103,948 to Wayne State University to investigate the role of the Ran guanine exchange factor, RCC1, in pancreatic ductal adenocarcinoma (PDAC) progression. The objectives are to study how RCC1 impacts PDAC metabolic activity and mRNA processing, as well as examine the effects of RCC1 overexpression on PDAC development and metastasis using animal models. The award period runs...
This $657,776 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a highly tumor-selective pan-RAS inactivator for targeting oncogenic RAS-driven cancers. The award will fund comprehensive characterization and evaluation of this novel agent's anti-tumor activity using a wide range of tumor models. The objective is to develop a tumor-selective, safe, and highly potent pan-RAS inactivator that has high clinical utility for...
This $370,575 project grant from the National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research at the University of Cincinnati investigating the molecular mechanisms of growth in pancreatic cancer with GNAS mutations. The grant supports studies from August 1, 2022 to July 31, 2027 to further the understanding of the oncogenic functions of mutant GNAS and its downstream signaling pathways. Specifically, the research will illuminate...
The National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) federal grant program, awarded a $110,550 project grant to The Trustees of the University of Pennsylvania on Sep 10, 2025. The grant supports research to investigate the mechanisms of lymphatic metastasis in pancreatic ductal adenocarcinoma. The key objectives are to evaluate transient depletion of regulatory T cells in lymph nodes as a therapeutic strategy, and determine how regulatory T cells suppress...
The National Institutes of Health's National Cancer Institute awarded a $283,136 Project Grant to the Regents of the University of Michigan under the Cancer Research Manpower federal grant program (CFDA 93.398). The award will support research investigating cellular communication in the tumor microenvironment of pancreatic cancer. The grantee will examine how hedgehog signaling alters the immune landscape and endothelial cell function through fibroblast interactions. They will also determine the...
This Project Grant award, with a total funding of $138,742, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The primary awardee, The Johns Hopkins University, will utilize single-cell RNA sequencing data to develop statistical methods for identifying cellular interactions that are altered by combination immunotherapy treatments in pancreatic ductal adenocarcinoma (PDAC). Additionally, the award will support experiments...
The National Cancer Institute (NCI) awarded a $159,540 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of North Carolina at Chapel Hill. The grant supports research to mechanistically examine and inhibitor target nutrient scavenging processes, including macropinocytosis and autophagy, for the treatment of pancreatic cancer. The research aims to understand how inhibitors of the KRAS-ERK MAPK pathway regulate these metabolic processes over time, and determine if upregulation of macropinocytosis confers resistance to dual autophagy and RAS-pathway inhibition. Findings from this work are expected to inform the future development of RAS-pathway inhibitor combinations for pancreatic cancer. The project period runs from Dec 1, 2024 to Jun 30, 2027.